This country profile provides an overview of Mauritania’s progress in reaching those in need of mass NTD treatment based on 2019 data.
*This includes all countries in Africa that are endemic for at least one of the five NTDs
Mauritania does not require mass treatment for elephantiasis.
Mauritania is conducting post-preventive chemotherapy surveillance.
Mauritania does not require mass treatment for intestinal worms.
Treatment coverage decreased from 77% in 2018 to 56% in 2019.
Mauritania does not require mass treatment for river blindness.
The ESPEN portal (a World Health Organization AFRO region project) provides maps and district-level data for the preventive chemotherapy diseases in Mauritania.